Pfizer, ec

Pfizer Secures Approval for Hemophilia Drug Hympavzi in the EU
Pfizer PFE announced that the European Commission (“EC”) has granted marketing authorization for Hympavzi (marstacimab) to treat certain hemophilia patients.With this nod, the once-weekly Hympavzi gets approved for routine prophylaxis (RP) to prevent or reduce the frequency of bleeding episodes in patients aged 12 years and older with hemophilia A or B,
Pfizer’s HYMPAVZI for Hemophilia A or B receives EU approval
The European Commission has approved Pfizer’s treatment for adults and adolescents with severe hemophilia A or B.
EC approval for Pfizer’s Hympavzi
The European Commission (EC) has granted marketing authorization for Hympavzi (marstacimab), from US pharma giant Pfizer. The drug is approved for the routine prophylaxis of bleeding episodes in patients 12 years of age and older weighing at least 35 kg with severe hemophilia A (congenital factor VIII [FVIII] deficiency,
Centessa drops phase 2 hemophilia B drug in wake of Pfizer’s Hympavzi approval
Centessa had recently conducted an interim analysis of a phase 2 study of its drug, called SerpinPC, which is designed to inhibit activated protein C. The analysis had demonstrated that SerpinPC had a favorable safety and tolerability profile, the U.K. and U.S.-based biotech said in its third-quarter earnings release.
EU Greenlights Pfizer's HYMPAVZI for Severe Hemophilia
Pfizer Inc. (NYSE: PFE) announced today that the European Commission (EC) has granted marketing authorization for HYMPAVZI™ (marstacimab) for the
Pfizer's HYMPAVZI Approved In EU For Treatment Of Severe Hemophilia A Or B Without Inhibitors
Drug major Pfizer Inc. (PFE) announced Wednesday that the European Commission or EC has granted marketing authorization for HYMPAVZI
Pfizer Gets European Approval of Hympavzi Hemophilia Drug
Pfizer said the green light makes Hympavzi the first once-weekly subcutaneous treatment in the European Union for people with severe hemophilia B and the first to be administered via a pre-filled pen or syringe for those with severe hemophilia A or B. The U.S. Food and Drug Administration approved Hympavzi in October.
Pfizer’s Hympavzi receives European marketing approval to treat adults and adolescents with severe haemophilia A or B without inhibitors
Pfizer’s Hympavzi receives European marketing approval to treat adults and adolescents with severe haemophilia A or B without inhibitors: New York Thursday, November 21, 2024, 0
Pfizer announces EC approval for Hympavzi
Pfizer (PFE) announced that the European Commission, or EC, has granted marketing authorization for Hympavzi for the routine prophylaxis of
EC marketing authorisation granted to Pfizer’s HYMPAVZI for haemophilia
The European Commission (EC) has granted marketing authorisation for Pfizer's anti-tissue factor pathway inhibitor (anti-TFPI), HYMPAVZI (marstacimab), to treat prophylaxis of bleeding incidents in individuals aged 12 years and above weighing a minimum of 35kg with severe haemophilia A without factor IX (FIX) inhibitors.
Zacks.com on MSN18h
Pharma Stock Roundup: EU Nod for PFE's Hympavzi, NVS Ups Sales View
This week Novartis NVS upgraded its mid-term sales growth guidance. The European Commission approved Pfizer’s PFE hemophilia ...
pharmaphorum3d
Pfizer bags EU okay for haemophilia drug Hympavzi
Pfizer's Hympavzi has become the first once-weekly subcutaneous treatment for people living with severe haemophilia B in the EU that can be delivered via an autoinjector device at home.